NDAORALCAPSULEPriority Review
Approved
Dec 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
METOPIRONE (metyrapone) by Esteve is adrenal steroid synthesis inhibitors [moa]. Approved for adrenal steroid synthesis inhibitor [epc]. First approved in 1961.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Metopirone (metyrapone) is an oral adrenal steroid synthesis inhibitor that blocks 11β-hydroxylase, the final enzyme in cortisol production. It is indicated for diagnostic testing of adrenal function and therapeutic management of severe hypercortisolism when surgery is not feasible or has failed. The drug reduces excessive cortisol levels by inhibiting the adrenal synthesis pathway.
$0.001BPart D
LOE ApproachingNiche endocrine product with minimal commercial scale (109 Part D claims in 2023); career growth limited to small specialty team focused on rare hypercortisolism indications.
Mechanism of Action
Adrenal Steroid Synthesis Inhibitors
Pharmacologic Class:
Adrenal Steroid Synthesis Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Metyrapone as Additive Treatment in Major Depression
Started May 1998
63 enrolled
Major Depressive Disorder
Career Relevance
Working on Metopirone offers deep expertise in rare adrenal disease and niche endocrinology but limited career scale or advancement. The product is ideal for professionals seeking specialization and direct physician relationships in a rare disease setting rather than broad commercial growth.
Medical Science Liaison (specialty endocrinology)
Worked on METOPIRONE at Esteve? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.